JP6931648B2 - 抗ｉｌ−１７ａ／ｆ抗体を用いた治療方法 - Google Patents

抗ｉｌ−１７ａ／ｆ抗体を用いた治療方法 Download PDF

Info

Publication number
JP6931648B2
JP6931648B2 JP2018521530A JP2018521530A JP6931648B2 JP 6931648 B2 JP6931648 B2 JP 6931648B2 JP 2018521530 A JP2018521530 A JP 2018521530A JP 2018521530 A JP2018521530 A JP 2018521530A JP 6931648 B2 JP6931648 B2 JP 6931648B2
Authority
JP
Japan
Prior art keywords
antibody
human
seq
weeks
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018521530A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018535961A (ja
JP2018535961A5 (https=
Inventor
グラット、ソフィー
イオネスク、ルシアン
ジョーンズ、マーガレット
オリヴァー、ルース
グラハム ショウ、ステヴァン
グラハム ショウ、ステヴァン
ストリメノポールー、フォテイニ
パヴァン クマール ヴァッジャー、ヴェンカタ
パヴァン クマール ヴァッジャー、ヴェンカタ
Original Assignee
ユーシービー バイオファルマ エスアールエル
ユーシービー バイオファルマ エスアールエル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57223670&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6931648(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ユーシービー バイオファルマ エスアールエル, ユーシービー バイオファルマ エスアールエル filed Critical ユーシービー バイオファルマ エスアールエル
Publication of JP2018535961A publication Critical patent/JP2018535961A/ja
Publication of JP2018535961A5 publication Critical patent/JP2018535961A5/ja
Priority to JP2021074962A priority Critical patent/JP6931750B2/ja
Application granted granted Critical
Publication of JP6931648B2 publication Critical patent/JP6931648B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2018521530A 2015-10-27 2016-10-26 抗ｉｌ−１７ａ／ｆ抗体を用いた治療方法 Active JP6931648B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021074962A JP6931750B2 (ja) 2015-10-27 2021-04-27 抗ｉｌ−１７ａ／ｆ抗体を用いた治療方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201562246989P 2015-10-27 2015-10-27
US62/246,989 2015-10-27
US201662303230P 2016-03-03 2016-03-03
US62/303,230 2016-03-03
US201662346826P 2016-06-07 2016-06-07
US62/346,826 2016-06-07
US201662405546P 2016-10-07 2016-10-07
US62/405,546 2016-10-07
PCT/EP2016/075821 WO2017072183A1 (en) 2015-10-27 2016-10-26 Methods of treatment using anti-il-17a/f antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021074962A Division JP6931750B2 (ja) 2015-10-27 2021-04-27 抗ｉｌ−１７ａ／ｆ抗体を用いた治療方法

Publications (3)

Publication Number Publication Date
JP2018535961A JP2018535961A (ja) 2018-12-06
JP2018535961A5 JP2018535961A5 (https=) 2019-12-05
JP6931648B2 true JP6931648B2 (ja) 2021-09-08

Family

ID=57223670

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2018521530A Active JP6931648B2 (ja) 2015-10-27 2016-10-26 抗ｉｌ−１７ａ／ｆ抗体を用いた治療方法
JP2021074962A Active JP6931750B2 (ja) 2015-10-27 2021-04-27 抗ｉｌ−１７ａ／ｆ抗体を用いた治療方法
JP2021092630A Active JP7176044B2 (ja) 2015-10-27 2021-06-01 抗ｉｌ－１７ａ／ｆ抗体を用いた治療方法
JP2022179423A Pending JP2023025019A (ja) 2015-10-27 2022-11-09 抗ｉｌ－１７ａ／ｆ抗体を用いた治療方法
JP2024203901A Pending JP2025037926A (ja) 2015-10-27 2024-11-22 抗ｉｌ－１７ａ／ｆ抗体を用いた治療方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2021074962A Active JP6931750B2 (ja) 2015-10-27 2021-04-27 抗ｉｌ−１７ａ／ｆ抗体を用いた治療方法
JP2021092630A Active JP7176044B2 (ja) 2015-10-27 2021-06-01 抗ｉｌ－１７ａ／ｆ抗体を用いた治療方法
JP2022179423A Pending JP2023025019A (ja) 2015-10-27 2022-11-09 抗ｉｌ－１７ａ／ｆ抗体を用いた治療方法
JP2024203901A Pending JP2025037926A (ja) 2015-10-27 2024-11-22 抗ｉｌ－１７ａ／ｆ抗体を用いた治療方法

Country Status (16)

Country Link
US (3) US11492396B2 (https=)
EP (1) EP3368570A1 (https=)
JP (5) JP6931648B2 (https=)
KR (2) KR20240156437A (https=)
CN (2) CN116059350A (https=)
AU (2) AU2016347471B2 (https=)
BR (1) BR112018008075A2 (https=)
CA (1) CA3001260A1 (https=)
CL (3) CL2018001135A1 (https=)
CO (1) CO2018004493A2 (https=)
IL (2) IL258515B1 (https=)
MX (4) MX2018005031A (https=)
MY (3) MY206805A (https=)
RU (1) RU2754683C2 (https=)
SG (2) SG11201802887PA (https=)
WO (1) WO2017072183A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
US20200277369A1 (en) * 2017-11-20 2020-09-03 Novartis Ag Method of treating hidradentitis suppurativa with il-17 antagonists
GB201719447D0 (en) * 2017-11-23 2018-01-10 Ucb Biopharma Sprl Pharmaceutical composition
WO2021050563A1 (en) * 2019-09-09 2021-03-18 The Rockefeller University Antibody treatment for lesional tissue of hidradenitis suppurativa
US20230167497A1 (en) * 2020-04-30 2023-06-01 Xiaohua Xue Methods of identifying modulators of the il-17 pathway
WO2022127842A1 (zh) * 2020-12-17 2022-06-23 上海华奥泰生物药业股份有限公司 靶向il-17a和il-36r的双特异性抗体及其应用
EP4471427A1 (en) * 2023-05-31 2024-12-04 Centre Hospitalier Universitaire De Nice Biomarker for spondyloarthitis diagnostic and response to treatment
CN117866905B (zh) * 2024-03-12 2024-06-04 北京贝来药业有限公司 基于纳米抗体基因修饰的干细胞及其制备方法和产品
US20260070969A1 (en) * 2024-09-11 2026-03-12 Paragon Therapeutics, Inc. Il-17 binding proteins, compositions, and methods of use thereof

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1995015982A2 (en) 1993-12-08 1995-06-15 Genzyme Corporation Process for generating specific antibodies
DE69534347T2 (de) 1994-01-31 2006-05-24 Trustees Of Boston University, Boston Bibliotheken aus Polyklonalen Antikörpern
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
ES2374068T3 (es) 2002-12-03 2012-02-13 Ucb Pharma, S.A. Ensayo para identificar células productoras de anticuerpos.
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
ES2551439T5 (es) 2003-07-01 2018-11-08 Ucb Biopharma Sprl Fragmentos Fab de anticuerpos modificados
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
WO2008039553A1 (en) 2006-02-10 2008-04-03 Zymogenetics, Inc. Soluble il-17rcx4 and methods of using in inflammation
EP1996622A2 (en) * 2006-03-10 2008-12-03 Zymogenetics, Inc. Antibodies that bind both il-17a and il-17f and methods of using the same
TW200815469A (en) 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
TW200902064A (en) * 2007-03-28 2009-01-16 Wyeth Corp Methods and compositions for modulating IL-17F/IL-17A biological activity
EP2535349A1 (en) 2007-09-26 2012-12-19 UCB Pharma S.A. Dual specificity antibody fusions
GB0807413D0 (en) * 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
RU2474588C2 (ru) * 2008-05-05 2013-02-10 Новиммун Са Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения
US8790642B2 (en) * 2008-08-29 2014-07-29 Genentech, Inc. Cross-reactive and bispecific anti-IL-17A/F antibodies
CA2737241C (en) 2008-09-26 2017-08-29 Ucb Pharma S.A. Multivalent antibody fusion proteins
RU2394575C1 (ru) * 2009-04-13 2010-07-20 Федеральное государственное учреждение "Уральский научно-исследовательский институт дерматовенерологии и иммунопатологии Федерального агентства по высокотехнологичной медицинской помощи" (ФГУ "УрНИИДВиИ Росмедтехнологий") Способ лечения псориаза
CN102458437B (zh) 2009-05-05 2015-06-10 诺维莫尼公司 抗il-17f抗体及其使用方法
WO2011030107A1 (en) 2009-09-10 2011-03-17 Ucb Pharma S.A. Multivalent antibodies
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
CN103154031A (zh) 2010-10-08 2013-06-12 诺华有限公司 利用il-17拮抗剂治疗牛皮癣的方法
ME02734B (me) * 2011-01-14 2017-10-20 Ucb Biopharma Sprl Antitelo koje vezuje il-17a i il-17f
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
EP2783014A1 (en) 2011-11-21 2014-10-01 Novartis AG Methods of treating psoriatic arthritis (psa) using il-17 antagonists and psa response or non- response alleles
WO2013158821A2 (en) 2012-04-20 2013-10-24 Novartis Ag Methods of treating ankylosing spondylitis using il-17 antagonists
GB201213571D0 (en) 2012-07-31 2012-09-12 Univ Leuven Kath Growth factor cocktail to enhnce osteogenic differentiayion of mesenchymal
LT2953969T (lt) * 2013-02-08 2019-12-10 Novartis Ag Anti-il-17a antikūnai ir jų panaudojimas autoimuninių ir uždegiminių ligų gydymui
WO2014155278A2 (en) 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
CN115957326A (zh) 2014-09-10 2023-04-14 诺华股份有限公司 使用il-17拮抗剂抑制银屑病关节炎患者的结构损伤进展
CA3002622A1 (en) 2015-10-19 2017-04-27 Novartis Ag Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (il-17) antagonists
GB201522391D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibody molecules
RU2680011C2 (ru) 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы

Also Published As

Publication number Publication date
JP2018535961A (ja) 2018-12-06
JP2021130707A (ja) 2021-09-09
MX2022009380A (es) 2022-09-07
US20230287100A1 (en) 2023-09-14
CN116059350A (zh) 2023-05-05
MY196489A (en) 2023-04-17
US20190292255A1 (en) 2019-09-26
CL2021002815A1 (es) 2022-07-29
BR112018008075A2 (en) 2018-12-04
JP6931750B2 (ja) 2021-09-08
JP7176044B2 (ja) 2022-11-21
US11492396B2 (en) 2022-11-08
MX2022009379A (es) 2022-09-07
MX2023004315A (es) 2023-05-08
MY207225A (en) 2025-02-06
CL2021002816A1 (es) 2022-07-29
WO2017072183A1 (en) 2017-05-04
RU2018118029A (ru) 2019-12-04
JP2023025019A (ja) 2023-02-21
AU2016347471B2 (en) 2023-08-03
MY206805A (en) 2025-01-08
AU2023255037A1 (en) 2023-11-16
IL258515A (en) 2018-05-31
IL325567A (en) 2026-02-01
AU2016347471A1 (en) 2018-05-10
SG10202112586WA (en) 2021-12-30
CN108350068A (zh) 2018-07-31
CA3001260A1 (en) 2017-05-04
CL2018001135A1 (es) 2019-05-10
CO2018004493A2 (es) 2018-11-30
MX2018005031A (es) 2018-06-13
IL258515B1 (en) 2026-01-01
SG11201802887PA (en) 2018-05-30
RU2754683C2 (ru) 2021-09-06
RU2018118029A3 (https=) 2020-09-17
JP2025037926A (ja) 2025-03-18
US20230279093A1 (en) 2023-09-07
JP2021119168A (ja) 2021-08-12
EP3368570A1 (en) 2018-09-05
KR20240156437A (ko) 2024-10-29
KR20180067676A (ko) 2018-06-20

Similar Documents

Publication Publication Date Title
JP6931750B2 (ja) 抗ｉｌ−１７ａ／ｆ抗体を用いた治療方法
JP5693844B2 (ja) ヒトｉｌ−１７に結合する抗体分子
RU2746926C2 (ru) Антагонистические антитела, которые связываются с человеческими TGFβ1, TGFβ2 и TGFβ3, и их применение при лечении фиброза легких
JP6028737B2 (ja) Ｉｌ−１７ａとｉｌ−１７ｆに結合する抗体分子
KR101761929B1 (ko) 인간 ｏｘ４０에 대한 특이성을 갖는 항체 분자
JP2019502380A (ja) ＴＮＦ−α、ＩＬ−１７Ａ及びＩＬ−１７Ｆに特異性を有する多重特異性抗体分子
TW202216198A (zh) 使用抗組織因子抗體之炎性疾病治療
KR20180089521A (ko) Tnf 알파에 결합하는 항체 분자
HK1187929B (en) Antibody molecules which bind il-17a and il-17f
HK1187929A (en) Antibody molecules which bind il-17a and il-17f

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191028

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191028

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201027

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210427

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210804

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210816

R150 Certificate of patent or registration of utility model

Ref document number: 6931648

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250